WHO Backs Rollout of Astrazeneca Vaccine
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Spotlight Briefing Note
Spotlight briefing Responding to the COVID-19 pandemic Ten questions on the next phase of the UK’s COVID-19 response October 2020 Overview • There are a number of questions which remain as to the next phase of the response to the COVID-19 pandemic. • What values have informed the most recent decisions on COVID-19 restrictions? Public health measures involve a number of challenging trade-offs between different rights and interests. Alongside the scientific evidence, it must be made clear which values are guiding decisions about which, and whose, interests take priority, and why. • Is the government considering the use of “immunity certificates” in the next phase of the response? Any approach which relies on a system of ‘immunity certification’ raises a number of ethical questions concerning individual rights versus the public interest, and social justice. If the Government is considering such a system, there must be a robust and open debate now. • How will development of an effective COVID-19 vaccine affect uptake - and what should be done? Issues around the speed of development, changes in regulation, and communication with the public may all affect public trust and uptake of any vaccine. Consideration about how to address these issues should take place now. • What discussions are taking place on setting priorities for vaccine allocation within the UK? There is a range of different values which can be taken into consideration when setting priorities for access to limited doses of a vaccine. What values and interests will guide decision-making in this area must be clearly set out. • How will the UK ensure a sustained commitment to global solidarity? The global nature of the pandemic shows the importance of working as part of a global effort. -
23 April 2020 Update
20 April – 23 April 2020 Contents I. Summary .............................................................................................................................1 II. European Union .................................................................................................................5 III. France ...............................................................................................................................6 IV. Italy ...................................................................................................................................7 V. Germany ............................................................................................................................8 VI. Spain ...............................................................................................................................10 VII. United Kingdom .............................................................................................................10 I. SUMMARY Number of cases: 1,009,762 (including the UK) Number of deaths: 108,223 • The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a meeting on 15 April to discuss the progress of the measures regarding availability of medicines for European patients during the COVID-19 pandemic. They also updated the Q&A document on regulatory expectations for medicinal products for human use during the COVID-19 pandemic on 20 April. On 21 April, they set-up the fast-track system to support essential medicines for COVID-19 treatment, -
Written Evidence from Spotlight on Corruption1 (PGG18) the Public
Written evidence from Spotlight on Corruption1 (PGG18) The Public Administration and Constitutional Affairs Committee Propriety of governance in light of Greensill inquiry Introduction The revelations arising from the Greensill affair and its fallout, coming alongside other recent and ongoing scandals, have exposed significant weaknesses in the UK system for managing conflicts of interest, lobbying, and business appointments. This is a vital opportunity to bring the UK’s standards landscape up to date, and to ensure that integrity and ethics in government are regulated in a way that befits a modern democracy. Taking action to strengthen the UK’s integrity and ethics framework would benefit the UK by helping to: build trust in politicians and government; strengthen the stability, predictability and attractiveness of the UK as a place to do business; give the UK greater credibility on the international stage in promoting democracy and good governance; and implement outstanding recommendations made by international bodies such as the UN and Council of Europe about how the UK can improve its integrity and ethics framework to prevent and tackle corruption. Key Recommendations 1. Integrity and Ethics legislation. The government should consult on the introduction of an Integrity and Ethics Bill, by the spring of 2022, which gives legislative effect to: the Law Commission’s recommendations on the introduction of a corruption in public office offence; recommendations made by international bodies to put ACOBA and the Independent Advisor on Ministerial Interests on a statutory footing; recommendations that are likely to be made by the Committee on Standards in Public Life’s Standards Matters 2.0 review in the Autumn of 2021; and recommendations likely to be made from both the Boardman review and parliamentary committees such as PACAC, including legislative reform to the Lobbying Act. -
UK COVID-19 Vaccines Delivery Plan
UK COVID-19 vaccines delivery plan Published 11 January 2021 Contents 1. Ministerial foreword ....................................................................................................... 3 2. Executive summary and scope ..................................................................................... 4 Supply .............................................................................................................................. 5 Prioritisation ...................................................................................................................... 6 Places ............................................................................................................................... 7 People .............................................................................................................................. 8 Tracking our progress ....................................................................................................... 9 3. Supply ......................................................................................................................... 10 Developing new vaccines ............................................................................................... 10 Ensuring vaccines meet strict safety standards for deployment ..................................... 17 Building UK manufacturing capability ............................................................................. 21 4. Prioritisation ............................................................................................................... -
Whole Day Download the Hansard
Monday Volume 681 28 September 2020 No. 109 HOUSE OF COMMONS OFFICIAL REPORT PARLIAMENTARY DEBATES (HANSARD) Monday 28 September 2020 © Parliamentary Copyright House of Commons 2020 This publication may be reproduced under the terms of the Open Parliament licence, which is published at www.parliament.uk/site-information/copyright/. HER MAJESTY’S GOVERNMENT MEMBERS OF THE CABINET (FORMED BY THE RT HON. BORIS JOHNSON, MP, DECEMBER 2019) PRIME MINISTER,FIRST LORD OF THE TREASURY,MINISTER FOR THE CIVIL SERVICE AND MINISTER FOR THE UNION— The Rt Hon. Boris Johnson, MP CHANCELLOR OF THE EXCHEQUER—The Rt Hon. Rishi Sunak, MP SECRETARY OF STATE FOR FOREIGN,COMMONWEALTH AND DEVELOPMENT AFFAIRS AND FIRST SECRETARY OF STATE— The Rt Hon. Dominic Raab, MP SECRETARY OF STATE FOR THE HOME DEPARTMENT—The Rt Hon. Priti Patel, MP CHANCELLOR OF THE DUCHY OF LANCASTER AND MINISTER FOR THE CABINET OFFICE—The Rt Hon. Michael Gove, MP LORD CHANCELLOR AND SECRETARY OF STATE FOR JUSTICE—The Rt Hon. Robert Buckland, QC, MP SECRETARY OF STATE FOR DEFENCE—The Rt Hon. Ben Wallace, MP SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE—The Rt Hon. Matt Hancock, MP SECRETARY OF STATE FOR BUSINESS,ENERGY AND INDUSTRIAL STRATEGY—The Rt Hon. Alok Sharma, MP SECRETARY OF STATE FOR INTERNATIONAL TRADE AND PRESIDENT OF THE BOARD OF TRADE, AND MINISTER FOR WOMEN AND EQUALITIES—The Rt Hon. Elizabeth Truss, MP SECRETARY OF STATE FOR WORK AND PENSIONS—The Rt Hon. Dr Thérèse Coffey, MP SECRETARY OF STATE FOR EDUCATION—The Rt Hon. Gavin Williamson CBE, MP SECRETARY OF STATE FOR ENVIRONMENT,FOOD AND RURAL AFFAIRS—The Rt Hon. -
COVID-19 Interim Vaccination Plan V.5 Pennsylvania
COVID-19 Interim Vaccination Plan V.5 Pennsylvania PA COVID-19 Vaccine Task Force/PA Department of Health JANUARY 19, 2021 |VERSION 5.0 PENNSYLVANIA COVID-19 INTERIM VACCINATION PLAN Table of Contents Introduction……………………………………………………………………………………………………………………………………….2 Section 1: COVID-19 Vaccination Preparedness Planning ......................................................................... 3 Section 2: COVID-19 Organizational Structure and Partner Involvement ................................................. 4 Section 3: Phased Approach to COVID-19 Vaccination ........................................................................... 11 Section 4: Critical Populations ................................................................................................................. 17 Section 5: COVID-19 Provider Recruitment and Enrollment ................................................................... 21 Section 6: COVID-19 Vaccine Administration Capacity ........................................................................... 25 1. Health and Medical Infrastructure .......................................................................................... 25 2. Occupational Health Clinics and Closed Points of Dispensing (PODs) ..................................... 26 3. Expanded Outreach to Ensure Vaccine Access ........................................................................ 27 4. Staffing .................................................................................................................................... -
Letter Tony Nikolic Wrote to New South Wales Minister
4. I am instructed to send this letter to sitting Members of Parliament (State and Federal). 5. The most recent Orders from the NSW State Government on Airport workers at Kingsford Smith Airport (Sydney) has caused a number of airport employees (including pregnant and single wage families/adults) to go on stress leave because they have been given an ultimatum to get the vaccine or potentially lose their positions. The amount of emails and calls from airline industry staff to my office is most concerning and I am instructed to make this representation on their behalf because they believe their elected representatives are not taking notice. 6. We are also mindful that the airport staff, front-line workers, pilots, police, paramedics and medical staff are also seeking the protection of all rights and responsibilities pursuant to Australian and International laws. 7. There are people taking sick leave from airport duties due to the mental health related issues and pressures being placed on them to take a vaccine. We understand that that the Australian Government cannot guarantee the vaccines safety in the short, mid and long term, but yet the NSW Government are issuing Orders for companies to vaccinate all staff, whilst Federal Parliamentarians do not question the validity or acknowledge this growing concern in electorates all over Australia. 8. I am instructed those workers are not allowed on Commonwealth airport property effective as of 6 July 2021 as a result of State Orders. The workers are not only feeling the pressures imposed upon them with speed and stealth at which the Orders were passed, but they are also concerned about being targeted if they speak out. -
Role and Responsibilities of the Chair of the Vaccine Taskforce
Chair of the Vaccine Taskforce Information pack for applicants Closing date: Midday on Friday 14 May 2021 Reference no: VAC-1775 Follow us on Twitter @appointmentsdh Table of Contents Section 1: Role, responsibilities and person specification.................................................... 2 Section 2: How to apply ....................................................................................................... 4 2.1 Making an application ............................................................................................. 4 2.2 The selection process ............................................................................................. 7 2.3 Eligibility criteria ...................................................................................................... 9 2.4 How we will manage your personal information .................................................... 10 Chair of the Vaccine Taskforce - Information pack for applicants Section 1: Role and responsibilities of the Chair of the Vaccine Taskforce The Chair must enable the Vaccine Taskforce to achieve their three core objectives during the pandemic period: a. To secure access to promising vaccine/s for the UK population. b. To make provision for international distribution of vaccines. c. To strengthen the UK’s onshore capacity and capability in vaccine development, manufacturing, and supply chain to provide resilience for this and future pandemics. In recognising that the Taskforce has now been in existence for over a year, delivering these objectives -
BMJ in the News Is a Weekly Digest of Journal Stories, Plus Any Other News
BMJ in the News is a weekly digest of journal stories, plus any other news about the company that has appeared in the national and a selection of English-speaking international media. A total of 25 journals were picked up in the media last week (21-27 September) - our highlights include: ● Research in The BMJ on excess belly fat and risk of early death was covered widely, including CNN, The Daily Mail and The Daily Telegraph. ● The New York Times ran an op-ed by Peter Doshi, Associate Editor at The BMJ on covid-19 vaccine trials. ● Research in Thorax warning that patients with no symptoms carry as much covid-19 virus as those with symptoms generated global headlines, including NBC News, New York Daily News and The Guardian. BMJ PRESS RELEASES The BMJ | BMJ Open Open Heart | Thorax EXTERNAL PRESS RELEASES BMJ Open | BMJ Open Diabetes Research & Care British Journal of Sports Medicine | Emergency Medicine Journal OTHER COVERAGE The BMJ | Annals of the Rheumatic Diseases Archives of Disease in Childhood | BMJ Evidence-Based Medicine BMJ Global Health | BMJ Nutrition, Prevention & Health BMJ Open Respiratory Research | Frontline Gastroenterology Gut | Heart Injury Prevention | Journal of Epidemiology & Community Health Journal of Medical Ethics | Journal of Neurology, Neurosurgery & Psychiatry Medical Humanities | Occupational & Environmental Medicine Postgraduate Medical Journal | Practical Neurology Vet Record B MJ New Co-Editors-in-Chief for BMJ Quality -
UKC Monthly Summary 2020 July.Odt
UK COLUMN CONTENT – July 2020 https://www.ukcolumn.org/ukcolumn-news-archive 01st July 2020 Brian Gerrish and Mike Robinson with today's UK Column News. START – Good news: excess mortality rate falls below five-year average Leicester local lockdown – police to spot-check cars leaving the restricted zone… Government provides details without showing any evidence to support them SAGE recommended ramping up fear and turning communities against each other The Ferguson effect: a similar situation occurred with Foot & Mouth – community division This policy seems deliberate by the UK ‘government of occupation’ Increased Covid-19 testing will obviously result in an increase in reported cases Is this a trial run and normalisation of ‘City State’ powers…? CoronaVirus found in waste water as early as March 2019 in Spain The spike in excess deaths across the world happened after lockdown… 15:49 – More fear: schools, hospitals and offices told to prepare for ‘marauding’ terror attacks Mail Online: is your teen secretly struggling with depression…? Mail Online: workers’ health starts to fail at the age of 59 MSM complains about Covid-19 infodemic – the ‘wrong’ kind of information… 19:28 – David Noakes (GcMAF) contact information CoronaVirus: Upper Crust owner blames lockdown for 5,000 UK redundancies Michael Gove quotes Franklin Delano Roosevelt in Brexit comments Gove suggests that change is coming to the UK Civil Service Boris announces a ‘new deal’ - ‘the opportunity is massive’ The MainStream Media reaction to Boris…? Nothing, silence… MSM too busy -
MCC VA COVID-19 Vaccine Provider FAQ May 2021
COVID-19 Vaccine Provider FAQs We are actively monitoring COVID-19 vaccine developments. Below you will find helpful information and answers to some of the most frequently asked questions about COVID-19 vaccines. Magellan Complete Care has a COVID-19 Vaccine Taskforce comprised of experts, including clinicians, health plan leadership, and pharmacy network team members that meets regularly to discuss the latest developments and plan support. We are monitoring government guidance at the federal and state levels. We are taking steps to ensure you have the information you need as the information and guidelines are made available by federal and state agencies. Vaccine Development and Distribution Operation Warp Speed (OWS) was set up by the White House to coordinate efforts among federal government entities, states, and private sector partners. It aims to accelerate the testing, supply, development, and distribution of safe and effective vaccines, therapeutics, and diagnostics. There are many government agencies involved in helping with the COVID-19 pandemic. A few of the key agencies are listed below for your reference: • Food and Drug Administration (FDA) – The FDA reviews and approves or authorizes safe and effective vaccines. • Centers for Disease Control and Prevention (CDC) – The CDC is responsible for controlling the introduction and spread of infectious diseases. • Advisory Committee on Immunization Practices (ACIP) – ACIP is a committee within the CDC that provides advice and guidance on effective control of vaccine-preventable diseases in the U.S. civilian population. • National Academies of Science Engineering & Medicine (NASEM) – The National Institutes of Health (NIH) and CDC have tasked NASEM to develop a plan for equitable allocation of vaccines. -
COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea
International Journal of Environmental Research and Public Health Article COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea Youngsuk Ko 1 , Jacob Lee 2, Yeonju Kim 3, Donghyok Kwon 3 and Eunok Jung 1,* 1 Department of Mathematics, Konkuk University, Seoul 05029, Korea; [email protected] 2 Division of Infectious Disease, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea; [email protected] 3 Division of Public Health Emergency Response Research, Korea Disease Control and Prevention Agency, Cheongju 28159, Korea; [email protected] (Y.K.); [email protected] (D.K.) * Correspondence: [email protected] Abstract: (1) Background: The vaccine supply is likely to be limited in 2021 due to constraints in manufacturing. To maximize the benefit from the rollout phase, an optimal strategy of vaccine allocation is necessary based on each country’s epidemic status. (2) Methods: We first developed a heterogeneous population model considering the transmission matrix using maximum likelihood estimation based on the epidemiological records of individual COVID-19 cases in the Republic of Korea. Using this model, the vaccine priorities for minimizing mortality or incidence were investigated. (3) Results: The simulation results showed that the optimal vaccine allocation strategy to minimize the mortality (or incidence) was to prioritize elderly and healthcare workers (or adults) as Citation: Ko, Y.; Lee, J.; Kim, Y.; long as the reproductive number was below 1.2 (or over 0.9). (4) Conclusion: Our simulation results Kwon, D.; Jung, E. COVID-19 Vaccine support the current Korean government vaccination priority strategy, which prioritizes healthcare Priority Strategy Using a workers and senior groups to minimize mortality, under the condition that the reproductive number Heterogenous Transmission Model remains below 1.2.